Demographic Characterization of Uveal Melanoma Population in Portugal

Authors

  • Sara Geada Department of Ophthalmology, Centro Hospitalar e Universitário de Coimbra (CHUC), Coimbra, Portugal; Clinical Academic Centre of Coimbra (CACC), Coimbra, Portugal https://orcid.org/0000-0002-6851-6201
  • Emmanuel Neves Department of Ophthalmology, Centro Hospitalar e Universitário de Coimbra (CHUC), Coimbra, Portugal; Clinical Academic Centre of Coimbra (CACC), Coimbra, Portugal
  • Tânia Teixeira Clinical Academic Centre of Coimbra (CACC), Coimbra, Portugal; Department of Radioncology, Centro Hospitalar e Universitário de Coimbra (CHUC), Coimbra, Portugal
  • Paulo César Simões Clinical Academic Centre of Coimbra (CACC), Coimbra, Portugal; Department of Radioncology, Centro Hospitalar e Universitário de Coimbra (CHUC), Coimbra, Portugal
  • Cristina Fonseca Department of Ophthalmology, Centro Hospitalar e Universitário de Coimbra (CHUC), Coimbra, Portugal; Clinical Academic Centre of Coimbra (CACC), Coimbra, Portugal
  • Rui Proença Department of Ophthalmology, Centro Hospitalar e Universitário de Coimbra (CHUC), Coimbra, Portugal; Clinical Academic Centre of Coimbra (CACC), Coimbra, Portugal

DOI:

https://doi.org/10.48560/rspo.28274

Keywords:

Melanoma/diagnosis, Melanoma/epidemiology, Melanoma/therapy¸Survival Analysis, Uveal Neoplasms/diagnosis, Uveal Neoplasms/epidemiology, Neoplasms/therapy

Abstract

INTRODUCTION: Uveal melanoma (UM) is the most common intraocular tumor and although rare, remains a clinical challenge for ocular oncologists. Therapeutic options have evolved throughout the years, focusing in eye-conserving modalities. However, long-term survival remains unchanged. Advances in early diagnosis and treatment represent a step forward in improving patients’ outcomes and survival. The purpose of this study is to characterize demographically and clinically the Portuguese population with uveal melanoma evaluated at the National Reference Centre (NRC).
METHODS: Prospective, observational study of patients consecutively diagnosed with UM at the Portuguese NRC, between January 2016 and December 2021. Data was collected regarding tumor characteristics, staging (American Joint Committee on Cancer – AJCC), demographic assessment, treatment modality, local control, patient survival and distant metastasis.
RESULTS: A total of 215 patients (53% female) were included. The mean age at diagnosis was 61.5± 14.0 years, with symptoms at presentation reported by 75.6%. Choroidal location was the most frequent (83.3%), followed by ciliary body (10.2%), iridociliary (3.3%) and iris (1.4%). The AJCC stage IIA and IIB were the most common at presentation (33.0% and 32.6%, respectively); stage IIIC was the less observed (n=3). Mean baseline basal diameter and thickness were, respectively, 11.7± 3.7 and 6.9±3.4 mm. Primary treatment comprised brachytherapy (n=152, 70.7%), enucleation (n=50, 23.3%), proton beam radiation (n=8, 3.7%) and tumor resection (n=5, 2.3%; only for iris tumors). Mean disease-specific survival (DSS) was 45.8 months (95%CI: 44.5-47.1 months), with a cumulative survival of 89.4 months (95%CI: 83.1-95.7) at 4 years. Mean distant metastases free survival (DMFS) was 53.4 months (95% CI: 50.8-56.0 months), with a cumulative survival of 83.9 months (95% CI: 76.7-91) at 4 years. Higher AJCC stages at presentation, enucleation and increased tumor thickness were associated with lower DSS and DMFS rates.
CONCLUSION: This is the first characterization of the Portuguese Population diagnosed with UM in the NRC. Our results highlight the importance of an early diagnosis given that almost 25% of patients were enucleated primarily and were not candidates for globe-sparing treatments. Lower AJCC stages and decreased tumor thickness at the time of diagnosis correlated with better DSS and DMFS, emphasizing the advantages of early treatment.

Downloads

Download data is not yet available.

References

Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998;83: 1664–78.

McLaughlin CC, Wu XC, Jemal A, Martin HJ, Roche LM, Chen VW. Incidence of noncutaneous melanomas in the U.S. Cancer. 2005;103:1000–7.

Aronow ME, Topham AK, Singh AD. Uveal melanoma: 5 year update on incidence, treatment, and survival (SEER 1973–2013). Ocul Oncol Pathol. 2018;4:145-51. doi: 10.1159/000480640.

Krantz BA, Dave N, Komatsubara KM, Marr BP, Carvajal RD. Uveal melanoma: epidemiology, etiology, and treatment of primary disease. Clin Ophthalmol. 2017;11:279-89. doi: 10.2147/OPTH.S89591.

Shields CL, Kaliki S, Furuta M, Mashayekhi A, Shields JA. Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases. Retina. 2012;32:1363–72. doi: 10.1097/IAE.0b013e31824d09a8.

Kaliki S, Shields CL. Uveal melanoma: relatively rare but deadly cancer. Eye. 2017;31:241–57. doi: 10.1038/eye.2016.275.

Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Biggeri A, EUROCARE Working Group et al. Incidence of uveal melanoma in Europe. Ophthalmology. 2007; 114: 2309–15.

Park SJ, Oh CM, Kim BW, Woo SJ, Cho H, Park KH. Nationwide Incidence of Ocular Melanoma in South Korea by Using the National Cancer Registry Database (1999–2011). Invest Ophthalmol Vis Sci. 2015; 56:4719–24. doi: 10.1167/iovs.1516532.

Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118: 1881–5.

Andreoli MT, Mieler WF, Leiderman YI. Epidemiological trends in uveal melanoma. Br J Ophthalmol. 2015; 99:1550–3. doi: 10.1136/bjophthalmol-2015-306810.

Baily C, O’Neill V, Dunne M, Cunningham M, Gullo G, Kennedy S, Walsh PM, Deady S, Horgan N. Uveal Melanoma in Ireland. Ocul Oncol Pathol. 2019;5:195-204. doi: 10.1159/000492391.

Shields CL, Furuta M, Thangappan A, Nagori S, Mashayekhi A, Lally DR, et al. Metastasis of uveal melanoma millimeterby-millimeter in 8033 consecutive eyes. Arch Ophthalmol. 2009; 127: 989–98.

Singh AD, Bergman L, Seregard S. Uveal melanoma: Epidemiologic aspects. Ophthalmol Clin North Am. 2005;18:75–84.

Lucena E, Goldemberg DC, Thuler LC, de Melo AC. Epidemiology of uveal melanoma in Brazil. Int J Retina Vitreous. 2020;6:51. doi: 10.1186/s40942-020-00261-w.

Damato EM, Damato BE. Detection and time to treatment of uveal melanoma in the United Kingdom: an evaluation of 2,384 patients. Ophthalmology. 2012;119: 1582–9.

Kivelä T, Simpson RE, Grossniklaus HE, editors. Uveal melanoma. In: AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2016. p.805-17.

Kaliki S, Shields CL, Shields JA. Uveal melanoma: estimating prognosis. Indian J Ophthalmol. 2015;63:93-102

Rantala ES, Hernberg MM, Piperno-Neumann S, Grossniklaus HE, Kivelä TT. Metastatic uveal melanoma: The final frontier. Prog Retin Eye Res. 2022;90:101041. doi: 10.1016/j.preteyeres.2022.101041.

American Brachytherapy Society - Ophthalmic Oncology Task Force. Electronic address: paulfinger@eyecancer.com; ABS – OOTF Committee. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy. 2014;13:1-14. doi: 10.1016/j.brachy.2013.11.008.

Singh AD, Topham A. Incidence of uveal melanoma in the United States: 1973–1997. Ophthalmology. 2003;110: 956–61.

Nichols EE, Richmond A, Daniels AB. Disparities in Uveal Melanoma: patient Characteristics. Semin Ophthalmol. 2016; 31: 296–303.

Alfaar AS, Saad A, Wiedemann P, Rehak M. The epidemiology of uveal melanoma in Germany: a nationwide report of incidence and survival between 2009 and 2015. Graefes Arch Clin Exp Ophthalmol. 2022;260:1723-31. doi: 10.1007/s00417021-05317-7.

Xu Y, Lou L, Wang Y, Miao Q, Jin K, Chen M, et al. Epidemiological Study of Uveal Melanoma from US Surveillance, Epidemiology, and End Results Program (2010-2015). J Ophthalmol. 2020;2020:3614039. doi: 10.1155/2020/3614039.

Rao YJ, Sein J, Badiyan S, Schwarz JK, DeWees T, Grigsby P, et al. Patterns of care and survival outcomes after treatment for uveal melanoma in the post-coms era (2004-2013): a surveillance, epidemiology, and end results analysis. J Contemp Brachytherapy. 2017;9:453-65.

Kujala E, Mäkitie T, Kivelä T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003; 44: 4651–9.

The AJCC Ophthalmic Oncology Task Force. International Validation of the American Joint Committee on Cancer’s 7th Edition Classification of Uveal Melanoma. JAMA Ophthalmol. 2015;133:376–83.

Messer JA, Zuhour RJ, Haque W, Lewis GD, Schefler AC, Wong A, et al. Eye plaque brachytherapy versus enucleation for ocular melanoma: an analysis from the National Cancer Database. J Contemp Brachytherapy. 2020;12:303-10. doi: 10.5114/jcb.2020.98108.

Zimmerman LE, McLean IW, Foster WD. Does enucleation of the eye containing a malignant melanoma prevent or accelerate the dissemination of tumour cells. Br J Ophthalmol. 1978; 62: 420-425.

Singh AD, Rennie IG, Kivela T, Seregard S, Grossniklaus H. The Zimmerman-McLean-Foster hypothesis: 25 years later. Br J Ophthalmol. 2004;88:962-7. doi: 10.1136/bjo.2003.029058.

Downloads

Published

2023-12-29

How to Cite

Geada, S., Neves, E., Teixeira, T., César Simões, P., Fonseca, C., & Proença, R. (2023). Demographic Characterization of Uveal Melanoma Population in Portugal. Revista Sociedade Portuguesa De Oftalmologia, 47(4), 265–272. https://doi.org/10.48560/rspo.28274

Issue

Section

Original Article